Disease Domain | Count |
---|---|
Neoplasms | 18 |
Hemic and Lymphatic Diseases | 4 |
Infectious Diseases | 2 |
Immune System Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Bispecific T-cell Engager (BiTE) | 3 |
Peptide Conjugate Radionuclide | 3 |
Autologous CAR-T | 2 |
Prophylactic vaccine | 2 |
Target |
Mechanism PSMA modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PSMA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GATA3 inhibitors |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2026 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator University of Bonn [+2] |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
NK cells(German Cancer Research Center) | Acute Myeloid Leukemia More | Phase 2 Clinical |
Human Papillomavirus Vaccine(German Cancer Research Center) | Human Papillomavirus Infection More | Phase 1 Clinical |
CC-1 ( CD3 x PSMA ) | Castration-Resistant Prostatic Cancer More | Phase 1 |
CC-3 ( CD276 x CD3 ) | Colorectal Cancer More | Phase 1 |
MDC-CAR-BCMA001(Dresden University of Technology) ( BCMA ) | Relapse multiple myeloma More | Phase 1 |